After finishing at $5.01 in the prior trading day, 2seventy bio Inc (NASDAQ: TSVT) closed at $4.92, down -1.80%. In other words, the price has decreased by -$0.0900 from its previous closing price. On the day, 4384326 shares were traded. TSVT stock price reached its highest trading level at $5.9000 during the session, while it also had its lowest trading level at $4.9150.
Ratios:
Our goal is to gain a better understanding of TSVT by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 3.98 and its Current Ratio is at 3.98. In the meantime, Its Debt-to-Equity ratio is 1.01 whereas as Long-Term Debt/Eq ratio is at 0.96.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Leerink Partners on January 31, 2024, Upgraded its rating to Outperform and sets its target price to $18 from $5 previously.
Leerink Partners Downgraded its Outperform to Market Perform on October 30, 2023, while the target price for the stock was maintained at $6.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Mar 26 ’24 when Casdin Capital, LLC bought 40,000 shares for $5.10 per share. The transaction valued at 203,992 led to the insider holds 2,000,000 shares of the business.
Casdin Capital, LLC bought 330,000 shares of TSVT for $1,673,991 on Mar 25 ’24. The Director now owns 1,960,000 shares after completing the transaction at $5.07 per share. On Mar 22 ’24, another insider, Casdin Capital, LLC, who serves as the Director of the company, bought 147,377 shares for $5.12 each. As a result, the insider paid 754,069 and bolstered with 1,630,000 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, TSVT now has a Market Capitalization of 252.96M and an Enterprise Value of 292.64M. For the stock, the TTM Price-to-Sale (P/S) ratio is 2.51 while its Price-to-Book (P/B) ratio in mrq is 0.98. Its current Enterprise Value per Revenue stands at 2.92 whereas that against EBITDA is -1.42.
Stock Price History:
Over the past 52 weeks, TSVT has reached a high of $12.69, while it has fallen to a 52-week low of $1.53. The 50-Day Moving Average of the stock is 5.0974, while the 200-Day Moving Average is calculated to be 4.9982.
Shares Statistics:
The stock has traded on average 1.40M shares per day over the past 3-months and 1.44M shares per day over the last 10 days, according to various share statistics. A total of 50.63M shares are outstanding, with a floating share count of 47.64M. Insiders hold about 6.84% of the company’s shares, while institutions hold 95.15% stake in the company. Shares short for TSVT as of Mar 15, 2024 were 5.25M with a Short Ratio of 3.74, compared to 5.81M on Feb 15, 2024. Therefore, it implies a Short% of Shares Outstanding of 10.23% and a Short% of Float of 10.36%.
Earnings Estimates
Its stock is currently analyzed by 6 different market analysts. On average, analysts expect EPS of -$0.75 for the current quarter, with a high estimate of -$0.26 and a low estimate of -$0.95, while EPS last year was -$1.08. The consensus estimate for the next quarter is -$0.59, with high estimates of -$0.16 and low estimates of -$0.95.
Analysts are recommending an EPS of between -$1.34 and -$3.28 for the fiscal current year, implying an average EPS of -$2.17. EPS for the following year is -$0.65, with 7 analysts recommending between $1.5 and -$1.59.
Revenue Estimates
6 analysts predict $15.28M in revenue for the current quarter. It ranges from a high estimate of $22.1M to a low estimate of $11.81M. As of the current estimate, 2seventy bio Inc’s year-ago sales were $22.3M, an estimated decrease of -31.50% from the year-ago figure. For the next quarter, 6 analysts are estimating revenue of $19.09M, a decrease of -47.00% less than the figure of -$31.50% in the same quarter last year. There is a high estimate of $30.67M for the next quarter, whereas the lowest estimate is $9.77M.
A total of 7 analysts have provided revenue estimates for TSVT’s current fiscal year. The highest revenue estimate was $130.3M, while the lowest revenue estimate was $47.15M, resulting in an average revenue estimate of $82.77M. In the same quarter a year ago, actual revenue was $100.39M, down -17.50% from the average estimate. Based on 7 analysts’ estimates, the company’s revenue will be $102.26M in the next fiscal year. The high estimate is $153.15M and the low estimate is $57.61M. The average revenue growth estimate for next year is up 23.50% from the average revenue estimate for this year.
